Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 1996
Business Overview: The Company develops, manufactures, and markets healthcare products, including contact lenses (CooperVision) and surgical instruments (CooperSurgical). It also provides healthcare services through psychiatric facilities (Hospital Group of America).
Key Financial Metrics
| Metric (in thousands) | Q1 1996 | Q1 1995 |
|---|---|---|
| Net Operating Revenue | $22,249 | $23,210 |
| Income from Operations | $1,699 | $980 |
| Net Income | $652 | $275 |
| Diluted EPS | $0.06 | $0.02 |
| Cash and Equivalents (End of Period) | $3,680 | $4,670 |
| Net Cash Used by Operating Activities | $(7,834) | $(5,008) |
| Total Debt (Current + Long-term) | $46,206 | N/A |
Note: Total Debt calculated as Borrowings under line of credit ($1,708) + Current installments ($831) + Long-term debt ($44,575).
Material Changes vs. Prior Period
- Revenue: Total net operating revenue decreased 4% to $22.2 million. Product sales increased 7% to $13.6 million, driven by CooperVision's toric lens growth. Service revenue (HGA) declined 17% to $8.7 million due to a transition of medical staff at Hampton Hospital and industry-wide managed care pressures.
- Profitability: Operating income improved 73% to $1.7 million. Net income more than doubled to $652,000. This improvement was aided by a 74% reduction in R&D expenses (from $1.1M to $277k) and a $167k credit for the settlement of disputes.
- Cash Flow: Operating cash outflows increased to $7.8 million, primarily due to $4.4 million in dispute settlements, $2.0 million in bonus payments, and increased working capital investments.
- Liquidity: Cash and cash equivalents dropped significantly from $11.2 million to $3.7 million during the quarter.
Guidance, Outlook, and Risks
- Fiscal 1996 Outlook: Management anticipates full-year earnings per share exceeding $0.75 and double-digit revenue growth.
- Segment Expectations:
- CooperVision: Expected mid-teens sales growth driven by market share gains in toric lenses.
- CooperSurgical: Anticipates completing the acquisition of Unimar, Inc. in Q2 1996, targeting 10% operating income margin for the combined business.
- HGA: Expected to outperform 1995 results following the Hampton Hospital turnaround and new outpatient clinics.
- Risks and Contingencies: Risks include changes in government reimbursement programs, competitive inroads, interest rate fluctuations, and the uncertainty of pending acquisitions. The Company is currently evaluating various acquisition opportunities.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of operations given the $7.8M operating cash outflow and the drop in cash reserves to $3.7M.
- Unimar Acquisition: Confirm the status of the Unimar, Inc. acquisition (signed letter of intent, subject to definitive agreement) and its impact on debt levels.
- HGA Turnaround: Monitor the stabilization of revenue at Hampton Hospital following the medical staff transition.
- Debt Structure: Review the composition of long-term debt, including the 10% Senior Subordinated Notes and HGA term loans, to assess refinancing risks.
- R&D Strategy Shift: Assess the long-term impact of significantly reduced R&D spending ($277k vs $1.1M prior year) on future product pipelines.